University of Vermont

College of Medicine

Department of Medicine


Bio for Julie Lin, M.D.
Julie Lin, M.D.

Julie Lin, M.D.

Assistant Professor of Medicine, Dermatology Medicine
Department of Medicine

Contact Information
Office Location:
Medicine-Dermatology, FAHC-ACC W. Pav. 5th Floor


Candidate for Graduate Certificate in Biomedical Informatics, 2009-present
Distance Learning Program, Department of Medical Informatics & Clinical Epidemiology
Oregon Health & Science University
Portland, Oregon

Dermatology Residency, 2006-2009
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania

Cutaneous Oncology Fellowship, 2005-2006
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania

NRSA Post-doctoral Research Fellowship, 2003-2005
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania

Internal Medicine Internship, 2002-2003
The Johns Hopkins University/Sinai Hospital Program in Internal Medicine
Baltimore, Maryland

McGill University, Faculty of Medicine, 1998-2002
Montreal, Quebec, Canada

Academic Interests

Medical Dermatology, Cutaneous T-cell lymphoma, Biomedical Informatics

Academic Appointments

Assistant Professor of Medicine, Dermatology

Publications (Peer Reviewed)

Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittoria C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP. Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. J Invest Dermatol. 2009 Apr 9.

Lin JH, Kim EJ, Bansal A, Seykora J, Richardson SK, Cha XY, Zafar S, Nasta S, Wysocka M, Benoit B, Rook AH, Fakharzadeh SS. Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. Blood. 2008 Sep 15;112(6):2484-8.

Yoon JS, Newton SM, Wysocka M, Troxel AB, Hess SD, Richardson SK, Lin JH, Benoit BM, Kasprzycka M, Wasik MA, Rook AH. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. J Invest Dermatol. 2008 Feb;128(2):473-80.

Richardson SK, Newton SB, Bach TL, Budgin JB, Benoit BM, Lin JH, Yoon JS, Wysocka M, Abrams CS, Rook AH. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol. 2007 Sep;82(9):792-7. PMID: 17546636

Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome. Clin Lymphoma Myeloma. 2006 Nov; 7(3):226-32. PMID: 17229339